HMN 2025: How Popular diabetes and weight-loss drug could scale back danger of dementia

Researchers on the Case Western Reserve School of Medicine have discovered that semaglutide, a preferred diabetes and weight-loss drug, could decrease the chance of dementia in folks with kind 2 diabetes (T2D).

Dementia, a {condition} that slowly makes it more durable for folks to recollect issues and assume clearly, happens when mind cells are broken and their connections cease working correctly. This harm, which worsens over time, might be attributable to numerous modifiable components, together with weight problems, T2D, cardiovascular ailments, traumatic mind damage and stroke.

According to the National Institutes of Health, greater than 6 million folks within the United States are recognized with dementia, and it causes greater than 100,000 deaths annually. Encouragingly, analysis signifies that 45% of dementia instances might be prevented by addressing modifiable danger components.

The study, revealed within the Journal of Alzheimer’s Disease , suggests T2D sufferers taking semaglutide had a considerably decrease danger of creating dementia in comparison with different antidiabetic drugs. These outcomes have been extra profound in girls and older adults.

Semaglutide, a glucagon-like peptide receptor (GLP-1R) molecule that decreases starvation and helps regulate blood sugar in T2D, can also be the energetic element within the diabetes and weight-loss medication Wegovy and Ozempic. Semaglutide has proven a broad vary of advantages, together with reductions in cardiovascular ailments.

The analysis staff—led by biomedical informatics professor Rong Xu—analyzed three years of digital information of almost 1.7 million T2D sufferers nationally. The researchers used a statistical strategy that mimics a randomized scientific trial.

They discovered sufferers prescribed semaglutide had a considerably decrease danger for Alzheimer’s disease-related dementia, in comparison with those that had taken any of seven different anti-diabetic drugs, together with different forms of GLP-1R-targeting drugs.

“There isn’t any remedy or efficient remedy for dementia, so this new study offers real-world proof for its potential impression on stopping or slowing dementia growth amongst an at-high-risk inhabitants,” stated Xu, who additionally directs the School of Medicine’s Center for AI in Drug Discovery and is a member of the Cancer Genomics Epigenomics Program on the Case Comprehensive Cancer Center.

Although their findings doubtlessly assist the concept semaglutide may forestall dementia, the research’s limitations prohibit the researchers from making agency causal conclusions, she stated.

“Our outcomes point out that analysis into semaglutide’s use for dementia prevention will should be additional investigated by randomized scientific trials,” Xu stated.